We Know They Work For Weight Loss — Here's What More Research Shows

For most women, weight loss is still the reason they start a GLP-1. That has not changed. What is new is that more of them come in curious, asking whether the medication also protects the heart, the kidneys, or their long term health. The short answer is that it can, and it is worth understanding why.

For most women, weight loss is still the reason they start a GLP-1. That has not changed. What is new is that more of them come in curious, asking whether the medication also protects the heart, the kidneys, or their long term health. The short answer is that it can, and it is worth understanding why.

So what is driving those extra benefits? Two things at once. 

Part of it is the weight loss itself, which takes strain off nearly every organ. But part of it is the drug working in ways that losing weight alone cannot explain. A GLP-1 does the familiar jobs. It helps your pancreas release insulin, it quiets the hormone glucagon, and it signals your brain that you are full. It also lowers inflammation and improves the lining of your blood vessels, and those effects reach well beyond your waistline.

Here is a point I want to be honest about, because you will see it overstated everywhere: People say these receptors1 sit directly inside your heart and kidneys, as if the drug plugs straight into each organ. The truth is more modest. 

The receptors mostly live2 in your blood vessels, your brain, and the pacemaker area of your heart, not in the working muscle of the heart or the filtering parts of the kidney. So the medication helps those organs mainly by an indirect route. It calms inflammation3, it steadies your blood vessels, and it improves your blood sugar and blood pressure. The organ benefits4 even when the drug is not acting on it directly.

The best proof that this is not just a weight story comes from the heart data. In the largest cardiovascular trial5, only about a third of the benefit tracked with how much weight a person lost. The rest came from something else, and early weight loss did not predict who did well. The medication is doing real biological work beyond shrinking fat.

Let me split this into what I trust and what I am still watching.

In STEP 98, semaglutide eased knee arthritis pain and improved function. I read that one with a caveat. Most of the benefit probably comes from carrying less weight on the joint. It is not FDA approved for arthritis.

Under all of it sits the foundation. STEP 19 established how much weight these drugs take off, and SURMOUNT-510 compared semaglutide and tirzepatide directly.

Interesting theories and promising biology, but no long term human outcome trials. We simply do not have the proof yet.

So what would move one of these maybe reasons into a real recommendation from me? A properly powered trial, in that specific group of patients, measuring something that actually matters to your life, not just a lab marker. Until that exists, I anchor the prescription to an approved reason you already qualify for, and treat any extra benefit as exactly that, a bonus.

Let’s start with what the trials show. In the randomized studies, semaglutide follows a clear pattern. The more you take, up to the target dose, the more effect you get, and the drug only becomes reliably effective once you reach those higher doses. We start low and move up slowly because your gut needs time to adjust, not because the low dose is doing the heavy lifting. So when a company markets a permanent tiny dose as a proven therapy, the controlled trial evidence for that is not there yet.

That said, I do not want to wave it all away. There is a growing body of real world experience with lower or less frequent dosing, and a lot of it comes from experienced, reputable providers who are watching their own patients closely. That kind of signal is worth taking seriously. It is plausible that for some people, especially for holding onto weight loss rather than achieving it in the first place, a lower dose does more than the trials would predict. We just do not have the controlled data yet to say who, or how much, or for how long. The one published paper 13on spacing out doses is only a two patient case series plus a pharmacology model, and even its authors call for proper randomized trials. So my honest position is cautious optimism. Interesting, plausible, not yet proven. I would let the experience and the data catch up before treating it as settled.

This is where I spend a lot of time reassuring patients. Yes, you lose some muscle. But the framing matters. When you lose a meaningful amount of weight by any method, whether surgery, a strict diet, or these drugs, some of it is lean mass14. That is normal physiology, not the drug melting your muscle.

In semaglutide trials15, lean mass made up roughly 40 percent of the weight lost at one year. One tirzepatide trial put it closer to 24 percent, similar to what you would see with a very low calorie diet. Real world data hint that tirzepatide may take a bit more relative lean mass than semaglutide. But step back. The large majority of what you lose is fat, which is the whole point.

What actually protects your muscle? Two things, and neither is exotic. Eat enough protein. I aim for about 1.6 grams per kilogram of body weight a day. And, most important, do resistance training. Lifting is what tells your body to keep the muscle it has. The trial designed to prove this out, called LEAN-PREP16, is running now. But you do not need to wait for the results to start protecting yourself. Protein and strength work, and we know that already.

GLP-1s are here to stay. I do not think that is a close call. Once you have hard outcome trials like SELECT, FLOW, and SURMOUNT-OSA, these stop being diet drugs and become cardiometabolic and preventive medicine. That is a different category entirely.

Will most adults be candidates within a few years? Time will tell. In a 2024 national poll, about one in eight U.S. adults had already tried one of these drugs, and given how common overweight and obesity are, a large share of people will qualify on paper as the approved uses expand. But being a candidate and needing to take it are not the same sentence. The cost is real, although more health insurance companies are getting on board as they see the benefits.